Although the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a 20% reduction in PCa-specific mortality by PSA screening, it also demonstrated a significant degree of overdiagnosis.[1] Therefore, a thorough stratification of the risk is important to provide the basis for clinical counseling and recommendations for screening to avoid overdiagnosis.[2]. This evidence concerns the gene KLK3 and prostate carcinoma.